C. Arth, et al. USSN 10/009,644 Page 3

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-8 (cancelled).

Claim 9 (new): A transdermal therapeutic system (TTS) for transcutaneous administration of tolterodine over a period of up to seven days, wherein the system comprises a layer of a tolterodine containing a matrix composition disposed on a carrier film, said matrix composition comprising a solid solution of (a) a copolymer of ethyl acrylate and methyl methacrylate containing about 5 % trimethylammonium ethyl methacrylate chloride as the sole (meth)acrylate copolymer, (b) at least one plasticizer and (c) up to 25 weight percent of tolterodine, and wherein the system is free of an adhesive layer.

Claim 10 (new): A transdermal therapeutic system for the transcutaneous administration of tolterodine over a period of up to seven days, wherein the system comprises a layer form of a tolterodine-containing matrix composition disposed on a carrier film, said matrix composition comprising (a) a copolymer of ethyl acrylate and methyl methacrylate containing about 5 % trimethylammonium ethyl methacrylate chloride as the sole (meth)acrylate copolymer, (b) at least one plasticizer, and (c) up to 25 weight percent of tolterodine, and that said matrix composition, with the exception of its release surface, is surrounded by a larger patch, which is free from active ingredient, for fixing to skin at the point of application.

Claim 11 (new): A TTS according to any one of claims 9-10, characterized in that the matrix composition which contains an active ingredient contains (R,S)-tolterodine or R-tolterodine.

Claim 12 (new): A TTS according to any one of claims 9-10, characterized in that the matrix composition which contains an active ingredient contains deuterated tolterodine.

C. Arth, et al. USSN 10/009,644 Page 4

Claim 13 (new): A TTS according to any one of claims 9-10, characterized in that the matrix composition which contains an active ingredient contains at least one triester of citric acid as the plasticizer.

Claim 14 (new): A TTS according to claim 13, characterized in that it contains tributyl citrate, on its own or in admixture with triethyl citrate, as the plasticizer.

Claim 15 (new): A TTS according to any one of claims 9-10, characterized in that the carrier film comprises a metallised or oxide coating on its matrix side.